Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.…
CAPR Stock Has Retail’s Attention After SLS Rally — Here Are 2 Drugs With Better FDA Approval Odds This Month
Capricor Therapeutics (NASDAQ: CAPR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 231 employees.
The shares were at 7.590 USD on 20 November 2026, up 20.9% over 52 weeks. Its 52-week range is 2.960 USD to 40.37 USD: the price is 81.2% below the high and 156.4% above the low.
Its market capitalisation is 441.30M USD.
Capricor Therapeutics reports return on equity of -34.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 105.35M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 27.25 USD is 259.0% above the current price. The next earnings report is expected on 11 March 2027.